Lipocine's Tlando Falls Short At US FDA Advisory Cmte Over Blood Pressure Concerns
Executive Summary
Oral testosterone's current clinical data could not definitely exclude elevated blood pressure, panelists vote.
You may also be interested in...
Keeping Track Of User Fee Decisions And Filings: Adakveo, Brukinsa And Fetroja Mark Massive Week Of Novel Approvals
The latest news on US FDA user fee decisions and submissions to the agency.
Keeping Track: Resubmissions For Tlando And Twirla NDAs, And A BTD For Pomalyst
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Approvals For Mayzent, Mavenclad, Duaklir, Jatenzo And Cimzia
The latest drug development news and highlights from our US FDA Performance Tracker.